SCI Abstract

search
+
Urinary microbiome-based metagenomic signature for the noninvasive diagnosis of hepatocellular carcinoma
Urinary microbiome-based metagenomic signature for the noninvasive diagnosis of hepatocellular carcinoma
Gut microbial dysbiosis is implicated in chronic liver disease and hepatocellular carcinoma (HCC), but the role of microbi...
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Inhibition of mutant KRAS challenged cancer research for decades. Recently, allele-specific inhibitors were approved for t...
wMKL: multi-omics data integration enables novel cancer subtype identification via weight-boosted multi-kernel learning
wMKL: multi-omics data integration enables novel cancer subtype identification via weight-boosted multi-kernel learning
Cancer is a heterogeneous disease driven by complex molecular alterations. Cancer subtypes determined from multi-omics dat...
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20
The repurposing of FDA-approved drugs for anti-cancer therapies is appealing due to their established safety profiles and ...
Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib
Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib
The MonarchE trial explored the use of abemaciclib, a CDK4/6 inhibitor, as an adjuvant treatment in high-risk early-stage ...
Identification of novel molecular subtypes to improve the classification framework of nasopharyngeal carcinoma
Identification of novel molecular subtypes to improve the classification framework of nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) treatment is largely based on a ‘one-drug-fits-all’ strategy in patients with s...
Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells
Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells
5-Fluorouracil (5-FU) remains a core component of systemic therapy for colorectal cancer (CRC). However, response rates re...
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
Gartisertib is an oral inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), a key kinase of the DNA damage r...
The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit
The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit
Understanding relationships between presenting symptoms and subsequently diagnosed cancers can inform symptom awareness ca...
Epithelial ovarian cancer survival by race and ethnicity in an equal-access healthcare population
Previous studies in the general population observed that compared with non-Hispanic White women, Pacific Islander and Blac...
Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, ...
Fatal and non-fatal breast cancers in women targeted by BreastScreen Norway: a cohort study
Fatal and non-fatal breast cancers in women targeted by BreastScreen Norway: a cohort study
Many breast cancer survivors experience anxiety related to dying from their disease even if it is detected at an early sta...
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia
Alterations of FLT3 are among the most common driver events in acute leukaemia with important clinical implications, since...
Stromal localization of inactive CD8+ T cells in metastatic mismatch repair deficient colorectal cancer
Stromal localization of inactive CD8+ T cells in metastatic mismatch repair deficient colorectal cancer
The determinants of metastasis in mismatch repair deficiency with high levels of microsatellite instability (MSI-H) in col...
Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression
Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression
N4-acetylcytidine (ac4C) is a conserved and abundant mRNA modification that controls protein expression by affecting trans...
Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy
Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy
The immune response has important clinical value in colorectal cancer (CRC) in both prognosis and response to immunotherap...
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis
Risk-reducing mastectomy (RRM) is offered to women with a BRCA1 or BRCA2 pathogenic variant, however, there are limited da...
Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
Aspirin as a possible treatment of cancer has been of increasing interest for over 50 years, but the balance of the risks ...
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review
There is little evidence on the balance between potential benefits and harms of mammography screening in women 75 years an...
Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer
Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer
Conventional chemotherapy is based on the maximum tolerated dose (MTD) and requires treatment-free intervals to restore no...
Multivitamin use and all-cause and cause-specific mortality in cancer survivors
Multivitamin use and all-cause and cause-specific mortality in cancer survivors
Despite no sufficient evidence on benefits and harms of multivitamin use, cancer survivors use multivitamins as a self-car...
Educational attainment in survivors of childhood cancer in Denmark, Finland, and Sweden
Educational attainment in survivors of childhood cancer in Denmark, Finland, and Sweden
Survivors of childhood cancer may face difficulties at school. We investigated whether childhood cancer affects attainment...
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges...
Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis
Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis
Neoadjuvant immunotherapy (nIO) has emerged as a treatment option for stage II–III triple-negative breast cancer (TN...
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia
The eukaryotic elongation factor, EEF1A2, has been identified as an oncogene in various solid tumors. Here, we have identi...
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy
High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and development have led to a growing...
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
CC-115, a dual mTORC1/2 and DNA-PK inhibitor, has promising antitumour activity when combined with androgen receptor (AR) ...
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells
Aberrant WNT/β-catenin signaling drives carcinogenesis. Tankyrases poly(ADP-ribosyl)ate and destabilize AXINs, β...
Comment on “Development and validation of a multivariable model for prediction of malignant transformation and recurrence of oral epithelial dysplasia”
Mahmood H, Shephard A, Hankinson P, Bradburn M, Araujo ALD, Santos-Silva AR, et al. Development and validation of a multiv...
Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with sparing on days 2–4 in cisplatin-base...
Load More
format_indent_increase